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Summary In a previous retrospective analysis from the principal paediatric centres of Algeria, Burkitt-type
lymphomas (BL) were shown to account for around 46.5% of the total childhood non-Hodgkin's malignant
lymphomas in that country. In the present study, a series of 49 abdominal BL from the Paediatric Clinic of
Surgery, Mustapha Hospital, Algiers, has been studied.
The age distribution shows a peak between 4 and 5 years of age, and the sex ratio is (M:F) 2.26:1. The
disease is characterized by a rapid evolution in the absence of therapy. The major problem is an explosive
form of the disease, which at present seems difficult to control in this country. Fifteen of the 49 patients
(30.6%) died before completion of the first course of chemotherapy; however, complete remission (CR) was
obtained for 30 patients (61%). Overall survival was 42.85% (21/49), whereas survival of patients who
reached CR is 70% (21/30). When CR was obtained, deaths were related to cerebrospinal fluid involvement,
local recurrence, secondary bone marrow involvement or therapeutic accidents. All patients alive with no
evidence ofdisease (NED) 8-months after CR can be considered definitively cured.
Epstein-Barr virus (EBV) serology performed on 31 BL patients and on a control group of 25 children
with other malignant tumours showed that most Algerian BL have elevated EBV titres. A search for viral
markers within malignant cells in 17 patients indicated that 88% (15/17) of the BL cases were EBV-
associated.
Analysis of the immunological and cytogenetic data showed that, as in the rest of the world, these BL cases
involve proliferation of B-cell-type lymphocytes, with characteristic cytogenetic translocations involving
chromosome 8.
This report represents the most detailed description so far of BL from an area in non-equatorial Africa and
the first report of a large series from North Africa.
Burkitt's lymphoma (BL) was initially described as
an African disease with particular epidemiological
characteristics which suggest than an infective agent
plays a role in its aetiology (Burkitt, 1958, 1962).
Morphological studies showed later that
lymphomas with similar histopathological features
occur in other parts of the world (O'Conor, 1965),
but occur with a much lower incidence. According
to a recent international working formulation, they
belong to the group of small non-cleaved, high-
grade non-Hodgkin's lymphomas (NHML)
(Rosenberg et al., 1982).
Whereas the clinical presentation differs
markedly from high- to low-incidence areas (jaw
predominance versus abdominal masses), these
rapidly growing tumours are very chemo-sensitive,
and rapid progress in treatment has been made
during the last years, reaching cure rates close to
70% (Bowman et al., 1982; Patte et al., 1982).
The Epstein-Barr virus (EBV), initially isolated
from an African BL tumour line (Epstein et al.,
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1964), can be considered as one of the causative
agents for BL cases occuring in high-incidence
central African regions (de The, 1978), where 96%
of tumours harbour the viral genome (Geser et al.,
1983). However, in low-incidence areas, most BL
tumours do not contain viral markers, and other
risk factors must be identified. Very recently it was
suggested that a crucial step in the development of
the malignant process is represented by the
chromosomal translocations found in BL tumours,
independent of their geographic origin.
Furthermore, these translocations - of three types:
t(8;14), t(8;22) or t(2;8) - might represent the best
markers of BL tumours (Berger et al., 1979;
Berheim et al., 1981).
There have been some detailed descriptions of
African BL outside the high-incidence areas: The
reports from North Africa that are available are
not well documented with regard to virological or
cytogenetic studies (Kalbian, 1967; Say et al., 1967;
Cammoun et al., 1972; Tinaztere et al., 1973;
Cehreli & Tosun, 1975; Capske & Kalifat, 1979).
More detailed data on Arab cases living in
Palestine have been published (Hulu et al., 1970;
Aghai et al., 1974; Gotlieb-Stematsky et al., 1976;
Goldblum et al., 1977; Buchner et al., 1978; Selzer
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et al., 1979a, b; Prokocimer et al., 1980), but no
significant survival study could be found.
We report here an analysis of 49 cases of
Algerian abdominal Burkitt-type NHML followed
at the Algiers Paediatric Surgery Unit between 1979
and 1982. This homogeneous series makes it
possible to define the clinical features of abdominal
BL in Algeria. The lack of other forms of clinical
presentation in this group of patients makes firm
epidemiological conclusions more difficult; however,
we hope that this report, which is the most detailed
description of BL from what is believed to be a
low-incidence area in Africa and the first significant
report from North Africa, will stimulate new
studies in other countries.
Patients and methods
From February 1979 to 30 December 1982, 49
abdominal Burkitt-type lymphomas were referred to
the Algiers Clinic of Paediatric Surgery. In 48
patients, a laparotomy was performed for tumour
removal (11 complete and 2 partial) or biopsy (35
cases). Cytological diagnosis alone was used for one
patient. Fifteen patients did not complete the first
course of chemotherapy after surgery because of
very bad general condition at referral and rapid
evolution of the tumour, leading to death within a
month. Twenty-two patients were treated
exclusively in Algiers; 22 were treated in Algiers for
induction and referred secondarily to Lyon (19
cases) or to the Institut Gustave-Roussy, Villejuif (3
cases); four patients were referred immediately to
France (3 to Lyon and 1 to Villejuif).
Pathological or cytological diagnosis was
performed in Algiers in all cases; 27 were reviewed
in France, and all confirmed as BL, while 16 were
diagnosed as BL in Algiers only (KB). Five cases
were diagnosed as lymphoblastic lymphoma in
Algiers and as BL in Lyon and were included in the
group of 49 patients as well as one lymphoblastic
lymphoma not reviewed in Lyon.
All but four patients (referred directly to France)
were staged in Algiers, by myelogram, chest X-ray,
complete blood count and echography. In 32
patients, examinations of marrow aspirates and of
cerebrospinal fluid (CSF) were performed. Staging
was done according to the classifications of
Murphy (1977) and Ziegler (1977) (Table I). When
neither marrow aspirates nor CSF examinations
were made, patients were classified as stage III/IV
by Murphy's classification.
Patients treated in Algiers received the COPAD
protocol (cyclophosphamide, vincristine, prednisone,
adriamycin), as modified at the Centre Leon
Berard, Lyon (Philip et al., 1980a), but with
60mgm-2 of adriamycin and 15mgm-2 intrathecal
methotrexate when available. Patients referred to
the Centre Leon Berard (21) or the Institut Gustave
Roussy (4) were treated by the French national
protocol (Patte et al., 1982). Three were treated by
massive therapy followed by autologous marrow
transplantation (two in Lyon, one in Paris) (Philip
et al., 1983; Hartemann et al., 1982).
In all cases complete remission (CR) was defined
as complete disappearance of all clinical symptoms
and at least a normal abdominal echography.
EBV virological studies were performed on 31 of
the 49 patients. Since 1982, one of us (YL) has
been sending tumours and sera from Algiers to the
International Agency for Research on Cancer
(IARC), Lyon (GML) as soon as possible after
laparotomy. Serological study was performed at
diagnosis or at referral to Lyon (or both).
EBV serology was performed at IARC for 29
patients by the indirect immunofluorescence
method (Lenoir et al., 1979). In 17 cases, EBV
nuclear antigen (EBNA) was measured in the
tumour cells. Twenty-five Algerian children with
other cancers referred to Centre Leon Berard
during the same period were studied with regard to
EBV status by serology and were used as controls
for this study.
BL cases were considered to be EBV-positive
only when EBNA was detected within the tumour
cells. Probable EBV positive BL was considered for
patients with VCA >640 and EA (D+R) >160
according to an IARC study (Geser et al., 1983),
other cases, either without EBNA study on tumour
cells or with only serological data, were considered
to be negative or probable negative BL (see Tables
III and IV).
In 10 cases, immunological membrane markers
were obtained in Lyon on the tumour cells. In nine
cases, a Burkitt continuous cell line was established
at IARC (Philip et al., submitted); cytogenetic data
are available, for these nine cases and for four
others (Mark-Vendel et al., 1983).
Results
The data obtained from our studies of the 49 cases
are summarized in Figures 1-6 and Table II.
Geographic, sex and age distribution
As shown in Figure 1, most patients were referred
from the Mediterranean coast of Algeria. The
patients comprised 34 males and 15 females (ratio,
2.26:1).
The age distribution by sex of patients is given in
Figure 2, indicating a peak incidence between the
ages of 4 and 5 years. The distribution between 2BURKITT'S LYMPHOMA IN ALGERIA 505
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Figure 1 Origin ofthe patients from Mediterranean parts ofAlgeria.
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Figure 2 Age distribution ofthe 49 cases of Burkitt lymphoma. M =males; F =females; Sex ratio =2.26: 1.
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and 16 years gives an average for the whole group
of 5.6 years.
Initial presentation
The interval between first symptom and diagnosis
was 2.4 months (4 days to 10 months). Referred
clinical symptoms were always abdominal tumours,
except that two patients had jaw tumours
associated with abdominal involvement. At the time
of the first clinical examination, complaints of
abdominal pain (23/49), vomiting (10/49), diarrhoea
or constipation (7/49), fever (6/49), weight loss
(4/19), neurological symptoms (2/49) and occlusion
(2/49) were noted.
As shown in Table II, by far the most frequent
site of presentation was the ileo-caecum (16/49).
Small-bowel involvement was seen initially in nine
patients with obvious clinical and pathological
difference from immunoproliferative small intestinal
disease (IPSID). A total of 16 patients presented
with diffuse involvement of the intestine. Only one
of the 15 females showed an ovarian tumour during
laparotomy and systematic examination of the
pelvis.
Staging
The Murphy classification (Murphy, 1977)
identified (Tables I and II) three patients with non-
extensive disease. Nine patients presented initially
with CSF (6) or bone-marrow (3) involvement.
Twenty patients were at stage III. Patients with no
CSF or bone marrow examination at diagnosis
were classified into stage III/IV; this group (17
patients) in fact represents a selection of those with
a very bad prognosis for whom there was not
sufficient time to perform the staging procedure
(Figure 3: see also Figure 6).
The Ziegler classification (Ziegler, 1977) (Tables I
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Figure 3 Percentage of survivors staged by the
Murphy classific.ation. (X) under treatment NED; (0)
out of treatment NED; (AL) alive in 2nd CR NED.
and II), which is specific for the abdominal form of
BL, shows a clear difference between non-extensive
disease (AR) and extensive disease (C and D). This
difference was associated with wide differences in
prognosis (as shown in Figure 4).
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Figure 4 Percentage of survivors staged by Ziegler
classification.
Table II Site of initial presentation and stage (Murphy and Ziegler classification) in 49 cases of abdominal
Burkitt lymphoma from Algeria
Site
Diffuse I Abdomen +
Ileo caecal Small involvement Mesenteric 1 other site
junction bowel ofthe intestine Kidney Ovary lymph nodes predominant
16 9 16 2 1 2 testis I
jaw 2
Stage (Murphy)
I>1 Unclassified
I II III IV (III/IV)
0 3 20 9 17
Stage (Ziegler)
A and B C D AR l
0 30 8 11
.T
--
.
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Evolution
Several points should be noted:
(1) Overall survival of the whole group was 42.8%
(21/49, Figure 5, profile 1).
100
Un
1. 70
-0 428
Diagnosis 1 2 3 4 5
Time (y)
Figure 5 Survival curves of all 49 cases of abdominal
BL, (D; comparison with those reaching a CR (30/49),
Q; and unpublished previous series from 1975-
1978 =25 patients, 0).
(2) Fifteen patients died before completing the first
course of chemotherapy (one Murphy stage III, one
stage IV and 13 stage III/IV). In this group the
interval between first symptom and diagnosis was
not significantly shorter (1.7 months) than that in
the whole group (2.42 months). They thus
correspond not to a later referral but to an
explosive form of the disease.
(3) Four patients died without going into CR, at
one, two, three and four months after diagnosis.
(4) CR was obtained in 30/49 patients. Survival in
this group is 70% (21/30) (Figure 5, profile 2); 17
of the 21 survivors were referred to France at some
period of the evolution of the disease. Nine patients
died after going into CR: two in CR, three with
CSF involvement, one with bone marrow
involvement, two with local relapse and one with a
maxillary relapse.
(5) As summarized in Figure 6, the majority of
deaths were due either to bad general condition at
referral or to immediate post-surgical evolution, as
described above (in point 2). Bacterial infections
and toxicity were other causes of death in this
group of patients. Only two patients died after
eight months of evolution, and these had been in
relapse before the eighth month after diagnosis.
Laboratory investigations
All 10 cases studied for membrane immuno-
globulins expressed heavy chains and either kappa
or lambda light chains, indicating monoclonality
and B-cell lymphomas.
EBV serology was done for 29 BL cases (Table
III) and 25 other childhood cancer patients (Table
IV). EBV titres were elevated in all but three BL
cases. The geometric mean titres (GMT) are as
follows: viral capsid antigen, 568; early antigen,
176, EB Nuclear Antigen, 163; compared with viral
capsid antigen, 120; early antigen, 2; EBNA, 32 for
controls. Determination of EBNA and/or viral
genome in tumour cells was possible in 17 cases
and was positive in 15: the EBV-BL association was
thus very elevated (88%), as in the central African
Cause Follow-up (months)
_____ 1 2 3 4 5 6 7 8 9 10 11 12
C.S.F.
Bone marrow l
Local relapse S
Immediate
postsurgery **
Bad general
condition s
Infection | * *
Toxicity |
Figure 6 Date and cause of the 26 deaths (2 lost for evaluation).
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(3)Table III EBV data on 31 patients
Anti-EBV antibodies
Cases VCA EA(d+R) EA(d) EBNA
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1280
640
640
160
>1280
, 1280
> 1280
640
320
320
>1280
,1280
160
80
640
80
320
320
80
1280
640
1280
1280
640
, 1280
640
640
, 1280
,1280
1280
160
640
80
640
, 1280
,1280
160
160
160
320
160
80
5
5
10
20
20
5
1280
160
1280
1280
160
1280
160
320
320
1280
160
5
5
5
320
40
80
320
5
40
5
80
<5
5
5
<5
10
<5
160
5
5
80
5
80
<5
40
5
10
1280
320
1280
160
80
, 1280
1280
160
320
160
10
40
160
320
80
640
160
40
320
1280
40
320
10
5
640
320
80
320
20
EBNA in
tumour cells
nd
nd
nd
nd
nd
nd
nd
nd
nd
nd
nd
nd
+d
+d
Conclusion
EBV+
EBV+
EBV+
EBV+
EBV+
EBV+
EBV+
EBV+
EBV+
EBV+
EBV+
EBV+
EBV+
EBV+
EBV+
EBV-
EBV-a
probable EBV-
probable EBV-
probable EBV-
probable EBV-
probable EBV+
probable EBV+
probable EBV+
probable EBV+
probable EBV+
probable EBV+
probable EBV+
probable EBV+
probable EBV+
probable EBV+
aProven also by molecular hybridation.
Table IV EBV control data in 25 children with cancer
EBV antibodies
EBNA Diagnosis
40
160
20
<5
320
40
10
<5
10
160
40
80
80
80
320
320
80
20
20
<5
80
40
10
<5
160
Benign angioma
Wilms
Wilms
Wilms
Wilms
Neuroblastoma
Wilms
Wilms
Medulloblastoma
Neuroblastoma
Neuroblastoma
Soft tissue sarcoma
Soft tissue sarcoma
Soft tissue sarcoma
Osteosarcoma
Osteosarcoma
Osteosarcoma
Ewing
Ewing
Thyroid anaplastic
carcinoma
Bowel carcinoma
Histiocytosis
Osteosarcoma
Ovarian carcinoma
Neuroblastoma
cases. Two BL cases were clearly EBV-negative.
Cytogenetic analysis (reported elsewhere: Mark-
Vendel et al., 1983) done on 13 tumours and/or
newly established cell lines showed BL-specific
translocation in all 13 cases: t(8;14) 10 times, t(2;8)
twice and t(8;22) once.
Discussion
In a recent histopathological study from Algeria
(Afiane & Chouiter, 1982), it was reported that BL
represents 46.5% of all childhood NHML, in
comparison with the 56% reported by Philip et al.
(1980b, 1982) and the 45.6% reported by Gerard-
Marchant et al. (1982) in France and the 33%
reported by Cosmann & Berard (1980) in the
United States. We have shown previously that in
Algeria 42 of 64 (65.6%) abdominal NHML were
BL (Chouiter & Ladjadj personal communication
1983). It is thus clear that BL represents the great
majority of abdominal NHML in children. This
finding confirms previous reports from non-
endemic regions outside Africa (Dorfmann, 1965;
Levine et al., 1982; Philip et al., 1982). During the
period 1980-1982 forty BLs were diagnosed in
children at Algiers. Among them 24 were ab-
dominal tumours (included in our 49 cases), 7 were
jaw tumours, 6 were nasopharynx or tonsil tumours
and 2 were isolated lymph nodes (Bendisari, un-
published data).
Cases
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
VCA
320
320
640
<5
160
320
320
<5
40
160
640
320
160
80
160
80
80
160
320
160
160
320
80
<5
320
EA
<5
20
<5
<5
<5
<5
<5
<5
<5
<5
<5
10
5
<5
<5
<5
S
20
<5
S
<5
10
<5
<5
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Abdominal Burkitt-type lymphoma is a clear
clinical entity accounting for at least 60% of all
Burkitt lymphomas in Algerian children. The age
incidence curve, which indicates a peak between 4
and 5 years is surprising in relation to the report of
Olweny from Uganda (Olweny et al., 1980) and to
reports from other parts of the world (Lenoir et al.,
1984). The peak of BL thus seems to be
younger in Algeria than in other countries,
although this finding must be confirmed by further
reports from this country. Our data allow definition
of the characteristics of abdominal BL: patients die
very quickly from a particular, explosive form of
the disease, whereas all patients alive NED eight
months after CR are still alive and can be
considered as cured. This finding confirms those of
previous reports (Philip et al., 1980a; Patte et al.,
1981). The overall survival of our patients is similar
to that of patients from countries with high socio-
economic levels (Philip et.al., 1980; Patte et al.,
1981). Figure 5, a comparison with previous series
from Algiers (0% survival in 1975-1978, see 3),
shows the progress made within a short period in
our country. The Ziegler classification (Figure 4)
clearly isolates that group of patients for whom
surgery plays a major role in obtaining a good
prognosis, although this group could represent a
selection, since complete excision is more often
proposed for smaller tumours. However, the
assumption that "there is no room for surgery in
BL" (Patte et al., 1981) should be reviewed,
especially in countries with a low economic level
where high technology and intensive chemotherapy
are not available.
This paper is the first to report clear indications
of an EBV association in BL from a non-endemic
area of Africa. The EBV association as measured
by the EBNA test was 88% in 17 cases studied. A
probable association based on EBNA and on
elevated EBV antibody titres was 80% in 31 cases
studied. This is in contrast to the serological data
on 25 control subjects with other solid tumours, in
whom the GMT for VCA was 120 versus 580 in the
BL patients. Similarly the GMT for EA (D+R)
was 2 in the controls and 163 in the BL cases. This
difference is quite significant (P<0.01) and the
value of EA (D+R) for determination of EBV
association in BL patients has been previously
reported (Geser et al., 1983; Lenoir, unpublished
data).
The incidence of BL among childhood cancers in
Algeria is not known, but may be very different
than in Europe because BL is believed to be the
most common childhood cancer in Algeria (Afiane
& Chouiter, 1982), whereas in France BL account
for only 3% of childhood cancer (Philip,
unpublished data). BL in Algeria might represent
between equatorial Africa and Europe an
intermediate incidence area for BL, and based on
this data the relationship between BL incidence and
EBV association remains unclear. Our report,
however, may indicate socio-economic level is more
important than incidence or geography as an
explanation of the EBV association with BL.
Algeria cannot be considered an endemic region for
BL, because of the intermediate incidence and the
prevalence of abdominal presentation with inter-
mediate incidence of jaw tumour (17%), but it
should be considered as a part of the world with a
high EBV association for BL.
It must be emphasized also that the present study
gives further examples of typical variant trans-
locations in BL (Mark-Vendel et al., 1983), and of
a complex three-way rearrangement (Philip et al.,
1981).
Algerian BL are comparable to European cases
with regard to clinical presentation and evolution
and to African cases with regard to EBV
association and socio-economic level of the
patients. In terms of incidence Algerian BL could
be considered as an intermediate area. For these
reasons, it appears to be a transitional model for
clinical research in BL. Our data strongly indicate
that North African countries should be included in
future epidemiological, virological, cytogenetical
and clinical investigations on BL.
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